Dr. Roger A Greenberg's lab at the University of Pennsylvania focuses on understanding how cancer cells with genomic instability can stimulate immune responses. They study the interactions between damaged DNA in cancer cells and the immune system, which can affect tumor growth and immune therapy effectiveness. The lab employs a multidisciplinary approach, integrating various techniques to explore these relationships and develop new therapies for cancer.

Dr. M. Celeste Simon's lab focuses on understanding clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer characterized by significant metabolic changes. The lab studies how these metabolic alterations impact tumor behavior and explores new therapeutic strategies to improve treatment outcomes for patients with not only ccRCC but also other related cancers. By utilizing advanced models, they aim to uncover universal metabolic pathways that could be targeted for personalized cancer therapy.

Dr. Matthew G. Vander Heiden's lab focuses on understanding how cancer cells alter their metabolism to support rapid growth and proliferation. By studying the unique metabolic requirements of different cancer types, the lab aims to discover how these processes can be targeted for cancer therapy. The research combines advanced techniques in biochemistry and mouse models to explore the limitations and variations in nutrient usage by cancer cells, providing insights that could lead to new treatments.

Dr. Donita C. Brady's lab at the University of Pennsylvania focuses on understanding cancer biology through a novel approach that combines chemistry and biology. The lab is developing a platform called Probe Enabled Activity Reporting (PEAR) to analyze dynamic changes in the tumor proteome, with the aim of improving targeted therapies and precision oncology. By studying cancer at the proteome level, the lab aims to enhance our understanding of how tumors adapt to therapies and identify new treatment strategies.

Dr. Ronald Anthony Depinho's lab at the University of Texas MD Anderson Cancer Center focuses on understanding how specific gene deletions in cancer cells can create unique vulnerabilities. By identifying these weak spots, the lab aims to develop precision cancer therapies that target only cancer cells while sparing normal ones. They utilize advanced techniques such as CRISPR to explore these genetic interactions and aim to improve treatment outcomes for cancer patients.

Dr. Cheryl A. London's lab at Tufts University focuses on improving cancer therapies through innovative research involving dogs. The lab works on enhancing the immune response in canine osteosarcoma by activating dendritic cells and also investigates clonal hematopoiesis in dogs to understand its implications for cancer treatment. Through clinical trials and the study of immune responses, the research aims to translate findings from canine models to improve human cancer therapies.

Dr. Robert B Rebhun's lab at UC Davis focuses on studying osteosarcoma in dogs, aiming to improve the understanding of this cancer to eventually enhance treatment for both dogs and humans. By investigating the tumor microenvironment and immune responses in naturally occurring cases, the lab seeks to establish better clinical outcomes for dogs and provide valuable insights for human cancer therapies. This work integrates veterinary science with comparative oncology to bridge gaps in translational research.

Dr. Saba Ghassemi's research focuses on improving CAR T cell therapies for cancer treatment. The lab is investigating ways to enhance the effectiveness of non-activated CAR T cells by targeting signaling pathways that affect their durability and function. By modulating specific pathways, the lab aims to develop strategies that reduce cancer immune evasion and improve the overall clinical outcomes for patients receiving these therapies.

Dr. Jennifer Michelle Davis' lab at the University of Washington focuses on understanding how the heart adapts to stress and injury, especially concerning the roles of cardiac muscle cells and fibroblasts in heart disease. By exploring how these cells respond to mechanical and molecular changes, the lab aims to identify new therapeutic approaches to improve heart function and prevent heart failure. Her research uses innovative techniques to manipulate and understand cellular processes that contribute to cardiac health and disease.

Dr. Edward Thorp's lab focuses on understanding how inflammation affects heart health, particularly in conditions like heart failure and ischemic injury. The lab investigates how different immune cells, specifically macrophages, interact with other heart cells to either worsen or alleviate inflammation. By exploring the underlying mechanisms and finding new pathways for intervention, the research aims to uncover potential treatments for heart diseases related to chronic inflammation.

Dr. Diego Fraidenraich's lab focuses on understanding how certain proteins in heart cells, particularly Connexin 43, are affected by Duchenne muscular dystrophy (DMD), a severe genetic disorder. The research explores how these changes contribute to heart problems associated with DMD and aims to develop new therapeutic strategies to protect heart function in affected patients. By utilizing advanced molecular techniques, the lab seeks to identify and manipulate the pathways that lead to cardiac complications in DMD.

Dr. Yigang Wang's lab focuses on understanding heart failure, a serious condition affecting millions globally. They explore how specific molecules, called miRNAs, impact heart cells and contribute to heart disease. By studying the mechanisms behind these processes, the lab aims to develop innovative therapies to mitigate heart failure and improve patient outcomes.

Dr. Md. Shenuarin Bhuiyan's lab at Louisiana State University focuses on understanding how a specific protein, Sigma 1 receptor, helps protect the heart under stress by regulating cell cleaning processes called macro-autophagy and mitophagy. The lab investigates the role of this receptor in heart failure to uncover new ways to treat the condition. Using genetically modified mice and advanced biochemical techniques, the lab aims to provide insights into the mechanisms that could lead to new therapies for heart diseases.

Dr. Junsu Kang's lab at the University of Wisconsin-Madison focuses on understanding how zebrafish can repair their hearts after injury. By studying the genetic and cellular mechanisms involved in this regeneration process, the lab aims to uncover potential strategies for healing hearts in humans, particularly after damage from disease or trauma. This innovative research could lead to groundbreaking treatments for heart diseases, which remain a leading cause of death worldwide.

Dr. Li Qian's lab at the University of North Carolina specializes in innovative strategies to repair heart tissue and improve heart function after injuries like heart attacks. By transforming cardiac fibroblasts into functional heart muscle cells using three specific transcription factors, the lab aims to advance therapies for heart failure, a major health issue. Their research combines cutting-edge techniques like single-cell analysis and mathematical modeling to better understand cardiac cell fate and enhance regenerative medicine approaches.

Dr. Il-Man Kim's lab focuses on understanding how to protect heart cells after a heart attack, which is crucial since the heart doesn't heal itself well. By studying specific molecules called microRNAs and their targets in heart cells and blood vessel cells, the lab aims to develop new therapies to improve heart healing and function. Their work combines laboratory models and human studies to explore how these molecules can be used to enhance recovery after heart damage.

Dr. Carl H. June's lab at the University of Pennsylvania focuses on developing advanced immunotherapies for blood cancers, particularly through the use of chimeric antigen receptor (CAR) T cell therapies. Their innovative research aims to extend these therapies beyond current limits by combining CAR T cells with genetic editing techniques. The lab works on a range of hematologic malignancies, including multiple myeloma and acute myeloid leukemia, aiming to transform the treatment landscape for these challenging diseases.

Dr. Marc Tatar's lab at Brown University explores how aging affects the communication between the kidney, adrenal glands, and heart. They focus on understanding a condition known as cardiorenal syndrome, where dysfunction in one organ can lead to problems in others, particularly in older adults. Through transplant experiments in mice, the lab examines how these interactions may promote fibrosis and contribute to age-related organ decline.

Dr. Rodrigo Del Rio's lab focuses on understanding how specific neurons in the brainstem control breathing and heart function, particularly in the context of heart failure with preserved ejection fraction (HFpEF). They use advanced techniques to map neuronal activity and gather physiological data to identify potential treatments that could improve heart and respiratory health. This research is crucial for developing new strategies to combat a prevalent health issue affecting millions.

Dr. Oren Rom's lab focuses on understanding the role of macrophages in cardiovascular diseases, particularly how their metabolism affects plaque stability in atherosclerosis. The research aims to uncover mechanisms behind macrophage behavior, specifically their ability to clear dead cells (efferocytosis) in arterial plaques. By restoring certain metabolic pathways, the lab hopes to find new therapeutic strategies to prevent harmful plaque ruptures and improve cardiovascular health.